The VirTrial platform enables the company to enable its selected clinical research sites to perform virtual tours – a combination of secure video, audio, chat, and messaging
BetterLife Pharma Inc (CSE: BETR) (OTCQB: BETRF) announced Thursday that it will partner with VirTrial LLC to conduct patient monitoring for its upcoming COVID-19 clinical trials in Australia to test the efficacy of AP-003, a proprietary formulation of interferon alpha 2b
VirTrial is a telehealth platform provider that is changing the way pharmaceutical companies conduct clinical trials and enabling research sites to improve patient recruitment and retention
BetterLife said VirTrial’s platform enables the company to enable its selected clinical research sites to perform virtual tours – a combination of secure video, audio, chat and messaging, that can be used on any device Virtual visit integration allows BetterLife to regularly assess, qualify and monitor patients and research sites for studies without physical travel
Unlike other clinical trial providers who started out as technology companies, BetterLife said that VirTrial has a stable team of clinical research veterans and seasoned technology entrepreneurs teaming up to direct the company towards remote access to the human population at clinical research sites
« Given the ever-changing travel restrictions due to COVID-19, we felt it was the best option for us to proceed with our patient trials without delay, » said the CEO from BetterLife, Dr Ahmad Doroudian in a statement“We believe that partnering with an innovative company like VirTrial will help us virtually monitor patients who may or may not be able to visit our clinical sites due to home self-isolation. »
Mark Hanley, CEO of VirTrial, added: “The sites are excited about the opportunity to be part of the solution for a real and current need and appreciate the benefit of being able to conduct the study via a fully remote DCT to eliminate any risk for employees «
In other company news, BetterLife announced that it has signed a share purchase agreement to sell the issued and outstanding shares of its subsidiary, Pivot Pharmaceuticals Manufacturing Corp to an unrelated third party. the company’s lease for the manufacturing plant in Dollard-des-Ormeaux, Quebec, Canada and its pending license application from Health Canada
The foregoing has been published by Proactive Investors Limited (the « Company ») on its website and is made available subject to the terms and conditions of use of its website (see T&C)
BetterLife Pharma Inc (OTCQB: BETRF) (CSE: BETR) CEO Ahmad Doroudian told Proactive he was encouraged by the positive results of a clinical trial conducted by a British biotech company, which suggested that interferon inhalation treatment for coronavirus reduces the need for intensive care
Doroudian says the data from
Market Indices, Commodities & Regulatory News copyright © Morningstar Data delayed by 15 minutes unless otherwise noted Terms of Service
Pivot Pharmaceuticals, Clinical Trial, Pharmaceutical Industry, Clinical Research, Coronavirus
World News – United States – BetterLife Pharma Announces VirTrial as Patient Tracking Partner for COVID Study -19 in Australia to test the effectiveness on AP-003
SOURCE: https://www.w24news.com
